[Sinovac: Category 1 new drug imidosifor for injection approved for marketing] On November 12, Sinovac (688837.SH) announced that the company received a notice from the National Medical Products Administration, approving the company’s independently developed Category 1 new drug imidosifor for injection to be launched on the market, with the trade name of Fornok, and its indications are hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. The drug was approved based on an international multi-center phase III clinical study, which showed that it was non-inferior to the control drug in terms of 14-day all-cause mortality and had good safety and tolerability. The company stated that this approval will help enhance its core competitiveness, but it is not expected to have a significant impact on this year's operating results.